Evidence brief
DSIP
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
DSIP, also called emideltide, is a peptide with nine amino acids. Small sleep studies from 1981 to 1992 used it through a vein. Some found short sleep changes. Others found little or no useful benefit. These studies do not prove that DSIP improves sleep or treats insomnia. DSIP is not an FDA-approved U.S. drug. A 2026 advisory vote did not add it to the current 503A list.
DSIP is a nine-amino-acid peptide. Studies do not prove it works. FDA has not approved DSIP.
- How strong is the evidence?
- Insufficient
Reliable studies in people are missing, too limited, or do not support the claim. This does not prove that the substance has no effect on the body. - What evidence exists?
- Investigational human outcomes
Studies measured health results in people, but the molecule is still being studied and is not approved for that use. Important questions remain. - Sports rules
- Not assessed
No current sports-rule review is available.
Reviewed August 30, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as Emideltide · Delta sleep-inducing peptide
Words used here
- peptide
- a short chain of amino acids
- amino acid
- a small building block that makes peptides and proteins
- investigational
- still being studied and not approved for that use
- outcome
- what the study measured
- molecule
- one specific chemical substance
- route
- how the product enters the body
- mechanism
- how a substance may cause a body change
- biomarker
- a body or lab measurement, not automatically a health benefit
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
Small older human studies gave DSIP mainly through a vein and reported mixed sleep results. The studies do not establish a treatment benefit.
Some studies measured short-term sleep or hormone changes after use through a vein. They do not define how DSIP acts in every person or product.
FDA found no adequate long-term safety data and no human safety evidence for the proposed under-the-skin route. Product quality and immune-reaction risks remain uncertain.
FDA separates free base and acetate. Online products may not match either form or the material used in human studies.
02 · Identity
What it is
DSIP, also called emideltide or delta sleep-inducing peptide, is a peptide with nine amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). Free base and acetate are different chemical forms. The 503A list is a U.S. list of bulk substances that may be used in some pharmacy compounding. A listed substance is not automatically an approved drug.
Scientific group: Sleep-related peptide. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
None identified in the United States.
- Small human studies of sleep
- Small human studies of withdrawal symptoms
04 · Research results
What the research shows
Small sleep studies from 1981 through 1992 tested DSIP, mostly through a vein. Some reported short sleep changes. Other controlled studies found little or no useful sleep benefit. One study measured a short-term change in a blood hormone, not better sleep. A few small studies also looked at narcolepsy or withdrawal symptoms.
These studies do not prove that DSIP improves sleep, treats insomnia, or treats opioid or alcohol withdrawal. The studies were small and used different designs. They do not show long-term benefit or safety. FDA's 2026 review found no adequate evidence for the proposed under-the-skin route and no long-term effectiveness data. It also found no adequate safety or toxicity record for the proposed use.
Exact product
DSIP is also called emideltide. FDA separates emideltide free base from emideltide acetate, a salt form. These forms are not automatically the same as each other or as a product sold online. A product name does not prove its identity, contents, quality, or match to study material.
05 · Claim check
Claims I checked
6 claims checked for this brief.
“DSIP and emideltide refer to the same nine-amino-acid peptide.”
Yes. FDA's substance and briefing records use emideltide for DSIP and identify a nine-amino-acid sequence. This name match does not make free base, acetate, or online products equivalent.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- FDA substance identity records for DSIP and emideltide; this does not establish the identity or quality of an online product. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“DSIP is proven to improve sleep or treat insomnia.”
Small older human studies had mixed results. Some used controls, while others had important design limits. Together, they do not prove that DSIP improves sleep or treats insomnia.
- Evidence used
- No reliable human outcome evidence. No reliable study in people shows the health outcome in this statement.
- Limits of this answer
- Small human sleep studies using different designs, products, routes, and follow-up periods; the results do not establish a general treatment benefit. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“DSIP treats opioid or alcohol withdrawal.”
Small older studies examined withdrawal symptoms, but they did not establish that DSIP treats opioid or alcohol withdrawal. The findings do not support a general treatment claim.
- Evidence used
- No reliable human outcome evidence. No reliable study in people shows the health outcome in this statement.
- Limits of this answer
- The small human withdrawal studies reviewed; this does not establish a treatment benefit for withdrawal or any other condition. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
Show 3 more claim checks
“DSIP is FDA-approved in the United States.”
FDA's briefing did not identify an FDA-approved U.S. drug containing emideltide. The current U.S. 503A list also does not list DSIP or emideltide. A substance record or a foreign or online product is not U.S. drug approval.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- United States approval and 503A status as reviewed August 30, 2026. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“The 2026 advisory vote added DSIP to the 503A list or approved it.”
The July 2026 committee vote was advisory. It did not itself change the 503A list or approve a drug. The current U.S. list does not show DSIP or emideltide, and no final FDA approval was identified in this review.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- The July 2026 advisory vote and United States 503A status as reviewed August 30, 2026; an advisory recommendation is not a final FDA decision or drug approval. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Emideltide free base, emideltide acetate, and online DSIP products are interchangeable.”
FDA separates emideltide free base and emideltide acetate. An online product may have a different form, contents, or quality. The names alone do not show that these products are interchangeable.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- Chemical-form and product-identity comparisons; this is not a use or administration recommendation. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about DSIP
No. An advisory vote gives advice to the FDA. It was not final FDA approval or a final listing decision for DSIP. The vote did not add DSIP to the current 503A list, and it does not make an online or compounded product FDA-approved.
No FDA-approved U.S. product; the July 2026 advisory vote did not add DSIP to the 503A list. No approved product is identified in the United States.
Not assessed. This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body. This status is not personal clearance to compete.
Small sleep studies from 1981 through 1992 tested DSIP, mostly through a vein. Some reported short sleep changes. Other controlled studies found little or no useful sleep benefit. One study measured a short-term change in a blood hormone, not better sleep. A few small studies also looked at narcolepsy or withdrawal symptoms.
These studies do not prove that DSIP improves sleep, treats insomnia, or treats opioid or alcohol withdrawal. The studies were small and used different designs. They do not show long-term benefit or safety. FDA's 2026 review found no adequate evidence for the proposed under-the-skin route and no long-term effectiveness data. It also found no adequate safety or toxicity record for the proposed use.
07 · Safety
Safety limits for this record
FDA identified important limits in the human safety and product-quality record. Free base, acetate, and online products may differ. This guide gives no dosing, administration, sourcing, product-selection, or treatment instructions.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
No current sports-rule review is available.
Reviewed .Check current rules for tested sport ↗08 · Sources
Read the sources
09 · Review history
Review history
Initial brief reviewed FDA identity and compounding records, the July 2026 advisory-committee record, and small human studies of sleep, hormone changes, narcolepsy, and withdrawal symptoms.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.